BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 21546295)

  • 21. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine.
    Campbell JP; Cobbold M; Wang Y; Goodall M; Bonney SL; Chamba A; Birtwistle J; Plant T; Afzal Z; Jefferis R; Drayson MT
    J Immunol Methods; 2013 May; 391(1-2):1-13. PubMed ID: 23388695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. POEMS Syndrome with IgG-λ/IgA-κ Biclonal Gammopathy and Abnormal Serum Free Light Chain Ratio: a Case Report.
    Ham JY; Suh JS; Lee WK; Song KE
    Ann Clin Lab Sci; 2015; 45(6):702-6. PubMed ID: 26663802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma].
    Chen HF; Hou J; Yuan ZG; Wang DX; Fu WJ; Chen YB
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):113-6. PubMed ID: 18681313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders.
    Vermeersch P; Vercammen M; Holvoet A; Vande Broek I; Delforge M; Bossuyt X
    Clin Chim Acta; 2009 Dec; 410(1-2):54-8. PubMed ID: 19778527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect.
    Shaheen SP; Levinson SS
    Clin Chim Acta; 2009 Aug; 406(1-2):162-6. PubMed ID: 19410572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.
    Djidjik R; Lounici Y; Chergeulaïne K; Berkouk Y; Mouhoub S; Chaib S; Belhani M; Ghaffor M
    Pathol Biol (Paris); 2015 Sep; 63(4-5):210-4. PubMed ID: 26294067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical usefulness of serum free light chain measurement in monoclonal gammopathy].
    Shimazaki C; Murakami H; Sawamura M; Matsuda M; Kinoshita T; Hata H; Sugiura I; Tsushita K; Nagura E; Kosugi H; Itoh J; Shimizu K
    Rinsho Ketsueki; 2010 Apr; 51(4):245-52. PubMed ID: 20467220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A wrong move in an amateur football player reveals a light chain myeloma].
    Peyneau M; Nassiri S; Myara A; Ohana S; Laplanche S
    Ann Biol Clin (Paris); 2016; 74(1):103-5. PubMed ID: 26878614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urine immunofixation electrophoresis remains important and is complementary to serum free light chain.
    Levinson SS
    Clin Chem Lab Med; 2011 Nov; 49(11):1801-4. PubMed ID: 21663562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
    Miyazaki K; Suzuki K
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of serum immunofixation electrophoresis and free light chain assays in the detection of monoclonal gammopathies.
    Wood PB; McElroy YG; Stone MJ
    Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):278-80. PubMed ID: 20709664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
    Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
    Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.
    Graziani MS; Merlini G
    Expert Rev Mol Diagn; 2014 Jan; 14(1):55-66. PubMed ID: 24308339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biochemical and immunological findings of multiple myeloma].
    Asaoku H
    Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay.
    Rosenberg AS; Bainbridge S; Pahwa R; Jialal I
    Clin Biochem; 2016 Oct; 49(15):1202-1204. PubMed ID: 27475249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concentrations of Serum Free Light Chains in Kappa and Lambda Lesions in Light-Chain Myelomas.
    Singh G
    Lab Med; 2019 Apr; 50(2):189-193. PubMed ID: 30423164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
    Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Multiple myeloma with monoclonal IgE gammopathy (author's transl)].
    Knedel M; Fateh-Moghadam A; Edel H; Bartl R; Neumeier D
    Dtsch Med Wochenschr; 1976 Mar; 101(13):496-9. PubMed ID: 943285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual light chain extramedullary myeloma presenting with mediastinal lymphadenopathy and lytic bone lesions.
    Vlachostergios PJ; Oikonomou KG; Hussain A; Abbi R; Balmiki RL
    Hematol Oncol Stem Cell Ther; 2016 Dec; 9(4):162-164. PubMed ID: 27000549
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.